Abstract
Background: Type 2 diabetes (T2DM) has been associated with deficiencies in serum magnesium level, decreasing insulin sensitivity and glucose metabolism. Glycosylated hemoglobin (Hb1Ac) is a biomarker of glucose values within the half-life of the erythrocyte, that is, 3 months. Low circulating and intracellular magnesium levels can modify glucose metabolism and insulin sensitivity. Renal solute management is a parameter little used to estimate circulating and excreted concentrations of elements such as magnesium.
Objective: The purpose of this study was to assess and associated fractional excretion of magnesium (FEMg) and serum magnesium with metabolic parameters, especially Hb1Ac percent, in a group of well characterized subjects with T2DM and non-diabetics subjects (ND).
Methods: According to Hb1Ac, two groups were compared and associated with existing biochemical parameters, included Hb1Ac, fasting glucose, lipid profile, serum creatinine, serum magnesium and urinary creatinine for FEMg.
Results: HbA1c levels were explained by serum magnesium in 25%. Serum magnesium levels in the ND group were higher than in the T2DM group and this was a statistically significant difference. Serum magnesium ≤1.8 is a risk factor (OD 16.1; P=0.021) for an HbA1c ≥ 6.5%.
Conclusion: In this study, hypomagnesemia was a parameter strongly associated with the diagnosis and progression of T2DM, while FEMg showed no significant association.
Keywords: Hypomagnesaemia, Fractional excretion of magnesium, glycosylated hemoglobin, type 2 diabetes, risk factor, nondiabetic.
Current Diabetes Reviews
Title:Deranged Fractional Excretion of Magnesium and Serum Magnesium Levels in Relation to Retrograde Glycaemic Regulation in Patients with Type 2 Diabetes Mellitus
Volume: 17 Issue: 1
Author(s): Corvera A.C. Esmeralda, Pedroza E. David, Irais C. Maldonado, Sharara Núñez A. Ibrahim, Alcántar S. David, Martha A.Q. Escorza and Delgadillo G. Dealmy*
Affiliation:
- Departamento de Farmacologia, Facultad de Medicina U.T., Universidad Autonoma de Coahuila. Torreon, Coah.,Mexico
Keywords: Hypomagnesaemia, Fractional excretion of magnesium, glycosylated hemoglobin, type 2 diabetes, risk factor, nondiabetic.
Abstract:
Background: Type 2 diabetes (T2DM) has been associated with deficiencies in serum magnesium level, decreasing insulin sensitivity and glucose metabolism. Glycosylated hemoglobin (Hb1Ac) is a biomarker of glucose values within the half-life of the erythrocyte, that is, 3 months. Low circulating and intracellular magnesium levels can modify glucose metabolism and insulin sensitivity. Renal solute management is a parameter little used to estimate circulating and excreted concentrations of elements such as magnesium.
Objective: The purpose of this study was to assess and associated fractional excretion of magnesium (FEMg) and serum magnesium with metabolic parameters, especially Hb1Ac percent, in a group of well characterized subjects with T2DM and non-diabetics subjects (ND).
Methods: According to Hb1Ac, two groups were compared and associated with existing biochemical parameters, included Hb1Ac, fasting glucose, lipid profile, serum creatinine, serum magnesium and urinary creatinine for FEMg.
Results: HbA1c levels were explained by serum magnesium in 25%. Serum magnesium levels in the ND group were higher than in the T2DM group and this was a statistically significant difference. Serum magnesium ≤1.8 is a risk factor (OD 16.1; P=0.021) for an HbA1c ≥ 6.5%.
Conclusion: In this study, hypomagnesemia was a parameter strongly associated with the diagnosis and progression of T2DM, while FEMg showed no significant association.
Export Options
About this article
Cite this article as:
Esmeralda A.C. Corvera , David E. Pedroza , Maldonado C. Irais , Ibrahim Núñez A. Sharara , David S. Alcántar , Escorza A.Q. Martha and Dealmy G. Delgadillo *, Deranged Fractional Excretion of Magnesium and Serum Magnesium Levels in Relation to Retrograde Glycaemic Regulation in Patients with Type 2 Diabetes Mellitus, Current Diabetes Reviews 2021; 17 (1) . https://dx.doi.org/10.2174/1573399816666200714150434
DOI https://dx.doi.org/10.2174/1573399816666200714150434 |
Print ISSN 1573-3998 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6417 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Omentin: Linking Metabolic Syndrome and Cardiovascular Disease
Current Vascular Pharmacology Therapeutic Prospects of PPARs in Psychiatric Disorders: A Comprehensive Review
Current Drug Targets An Update on Clinical Drug Interactions with the Herbal Antidepressant St. Johns wort
Current Drug Metabolism Recombinant Human Insulin-Like Growth Factor-1: A New Cardiovascular Disease Treatment Option?
Cardiovascular & Hematological Agents in Medicinal Chemistry Management of Primary Aldosteronism: Its Complications and Their Outcomes After Treatment
Current Vascular Pharmacology SIRT1 as a Novel Potential Treatment Target for Vascular Aging and Age-Related Vascular Diseases
Current Molecular Medicine Nitric Oxide, Peroxynitrite, Peroxynitrous Acid, Nitroxyl, Nitrogen Dioxide, Nitrous Oxide: Biochemical Mechanisms and Bioaction
Current Bioactive Compounds Microcirculation of the Diabetic Foot
Current Pharmaceutical Design Patent Selections
Recent Patents on Cardiovascular Drug Discovery May Oxygen-Ozone Therapy Improves Cardiovascular Disorders?
Cardiovascular & Hematological Disorders-Drug Targets Lipid-Lowering Therapies for Atherosclerosis: Statins, Fibrates, Ezetimibe and PCSK9 Monoclonal Antibodies
Current Medicinal Chemistry Maternal Sepsis 2010: Early Recognition and Aggressive Treatment with Early Goal Directed Therapy can Improve Maternal Outcomes
Current Women`s Health Reviews Evidence of Redox Unbalance in Post-Acute Ischemic Stroke Patients
Current Neurovascular Research Development and Clinical use of Prasugrel and Ticagrelor
Current Pharmaceutical Design Triglycerides and Vascular Risk: Insights from Epidemiological Data and Interventional Studies
Current Drug Targets Advanced Glycation End Products (AGEs), Oxidative Stress and Diabetic Retinopathy
Current Pharmaceutical Biotechnology Therapeutic Approaches in Vascular Repair Induced by Adult Bone Marrow Cells and Circulating Progenitor Endothelial Cells
Current Pharmaceutical Design MicroRNA Expression in Coronary Artery Disease
MicroRNA Systemic Biomarkers in the Evaluation and Management of COPD Patients: Are We Getting Closer to Clinical Application?
Current Drug Targets MRI Abnormalities Associated with Mild Cognitive Impairments of Vascular (VMCI) Versus Neurodegenerative (NMCI) Types Prodromal for Vascular and Alzheimers Dementias
Current Alzheimer Research